基于捕获技术的深度二代测序检测肺癌患者血浆EML4-ALK融合突变具有高灵敏度和特异性

来源 :第十八届全国临床肿瘤学大会暨2015年CSCO学术年会 | 被引量 : 0次 | 上传用户:zfhtang
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  目的:评估基于捕获技术的深度二代测序肺癌患者血浆棘皮动物微管相关蛋白样4-间变性淋巴瘤激酶(Echinoderm microtubule-associated-protein-like 4-anaplastic lymphoma kinase,EML4-ALK)融合突变的灵敏度和特异性。
其他文献
目的:局部进展期胃癌(Locally advancedgastric cancer,LAGC)D2根治术后是否需要辅助放化疗(Chemoradiotherapy,CRT)目前仍存在争议.INT0116试验证明术后辅助放化疗优于单纯手术,然而ARTIST研究结果表明与术后辅助化疗(Chemotherapy,CT)相比,辅助放化疗并未带来生存获益.
Objective: Recent studies indicate that autophagy is adouble-edged sword in tumor genesis and plays an important role in theresistance of cancer cells to chemotherapy.We hypothesize that autophagy pro
Objective: Small cell lung cancer (SCLC) is a refractory subtype of lung cancer characterized by limited drug responses, aggressive metastasis and relapse at relatively earlystage when compared to non
目的:甲苯磺酸多纳非尼是一种新开发的口服多激酶抑制剂类多靶点小分子抗肿瘤药物,可抑制VEGFR、PDGFR、Raf等多种受体激酶和其下游的Raf/MEK/ERK信号传导通路,达到抑制肿瘤细胞增殖和肿瘤血管新生的多重抗肿瘤作用。
Objective: To observe the efficacy and safety of pulsatile administration of high-dose gefitinib or erlotinib for advanced non-small cell lung cancer patients with secondary drug resistanceto standard
目的: Malignant pleuraleffusion (MPE) is mainly caused by metastatic pleuralcancer and defines malignant tumors with apoor prognosis.To achieve sufficient control of MPE and to minimize invasive interve
Objective: Along with the research progress of lung cancer-related driver genes, echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinas (EML4-ALK) positive non-small cell lung canc
目的: Twist1 over expression has been reported to correspond with poorsurvival in non-small cell lung cancer (NSCLC), but the underlining mechanismis not clear.The objective of the present study was to
会议
目的:探讨非小细胞肺癌组织中RET融合基因与胸苷酸合成酶(thymidylate synthase,TYMS)基因mRNA表达的关系。方法:应用实时荧光定量PCR方法检测642例NSCLC组织中RET基因以及TYMS基因mRNA的表达。
目的: Superiorefficacy of pemetrexed with favorable tolerability has been demonstrated in both of the 2nd-line and the maintenance setting for patients with non-squamousnon-small cell lung cancer (NSCLC